Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Nedosiran in Pediatric Primary Hyperoxaluria With Preserved Renal Function
2021-001083-16Phase 2Completed
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Jun 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH) and hyperoxaluria, sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Change in urinary oxalate-to-creatinine ratio at Month 6. Started Jun 2021; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)hyperoxaluria
Beyond the preview
Go deeper on 2021-001083-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001083-16.